OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.

Trial Details

NCT ID
NCT06466382
Phase
NA
Sponsor
Swiss GO Trial Group
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling
  • Carboplatin / Paclitaxel Chemotherapy
Locations (sample)
  • Baden, Canton of Aargau, Switzerland|47.47333,8.30592
  • Basel, Canton of Basel-City, Switzerland|47.55839,7.57327
  • Sankt Gallen, Canton of St. Gallen, Switzerland|47.42391,9.37477
  • Frauenfeld, Thurgau, Switzerland|47.55776,8.89893
  • Bern, Switzerland|46.94809,7.44744

Key Eligibility Criteria

  • Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV
  • No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis
  • Envisaged surgical candidate for interval debulking after 2 cycles of treatment
  • Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →